Bendamustine-Rituxan Combination Shows Promise in Frontline Treatment of Most Patients with Mantle Cell Lymphoma
September 2nd 2020, 1:00pm
Article“Moving forward, (bendamustine and Rituxan) will likely become a common backbone for the incorporation of other cytotoxic or novel agents in an attempt to further improve outcomes while maintaining an effective, safe, and ideally outpatient regimen for MCL,” the authors wrote.
